These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21575967)

  • 1. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
    Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
    Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Nickel JC; Hoefner K; Andriole G;
    Urology; 2002 Sep; 60(3):434-41. PubMed ID: 12350480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yang C; Yan H; Zhang Y
    Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.
    Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S
    JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
    Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
    BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dutasteride on the risk of prostate cancer.
    Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
    N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
    Rabasseda X
    Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
    Haque N; Masumori N; Sakamoto S; Ye Z; Yoon SJ; Kuo HC; Brotherton B; Wilson T; Muganurmath C; McLaughlin M; Manyak M
    Int J Urol; 2018 Nov; 25(11):944-951. PubMed ID: 30198102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.